NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced today that Sanofi (EURONEXT: SAN and NYSE: SNY), one of the world’s largest pharmaceutical companies, has selected BioClinica’s OnPoint as the company’s standard CTMS (Clinical Trial Management System). With this decision, Sanofi plans to utilize OnPoint CTMS for all clinical trial management activity.
Sanofi is the largest in a growing list of companies that includes other top ten pharmaceutical and medical device manufacturers to embrace BioClinica’s innovative clinical trial management system, making OnPoint the leading CTMS solution for forward-thinking companies.
“BioClinica is extremely proud that Sanofi has chosen OnPoint CTMS,” said Mark Weinstein, CEO of BioClinica. “We look forward to helping fulfill the long-term vision of Sanofi through the use of embedded and transformational applications. This is further evidence that our eClinical solutions are not only leading from a technology perspective, but that our people, products and services are some of the best in the industry.”
BioClinica’s OnPoint CTMS improves clinical trial management by helping sponsors easily centralize and share trial data. OnPoint’s unique Office-Smart design will maximize Sanofi’s existing investment in Microsoft technologies by letting users access, update, and report on clinical trial data from within the familiar environment of Microsoft Office and SharePoint. Using SharePoint as a collaborative portal, OnPoint’s web services integration with other trial management products provides an end-to-end trial management solution. This approach lessons the financial impact of trial management, greatly enhances user adoption, and helps avoid the pitfalls of outdated, legacy CTMS products.
“Providing an end-to-end clinical development platform that unifies the best available solutions is an important part of BioClinica’s approach to trial management,” said Peter Benton, President of BioClinica’s eClinical Solutions. “OnPoint’s ability to exchange information across multiple systems, including Sanofi’s choice of eTMF (Electronic Trial Master File), makes OnPoint the best choice for clinical trial management and demonstrates why BioClinica is the innovation leader in eClinical products.”
“I am confident that OnPoint is the right CTMS for Sanofi and will help bring new therapies and treatments to market faster,” continued Mr. Benton. “As part of Sanofi’s extensive evaluation process, we conducted a proof-of-concept implementation which demonstrated how OnPoint met Sanofi’s key business imperatives of collaboration, integration, and architectural openness.”
As a Microsoft Gold partner, BioClinica has long been known for its industry-leading integration with Microsoft technology. BioClinica was recently awarded a Microsoft Life Sciences Innovation Award for creating the OnPoint CTMS “Monitor Visit Report” which makes it easier for clinical site monitors to enter essential study information with or without an internet connection. Andrea McGonigle, national managing director for Life Sciences at Microsoft Corporation, stated, “BioClinica and Sanofi have both recognized the power of the Microsoft Platform and are using these technologies to build the future of how clinical trials will be run. The power of the Microsoft stack allows scalability and flexibility, and puts the information back in the users’ hands. Instead of monolithic database architectures, Sanofi will be empowered to ‘liberate their clinical trial data’ and make faster decisions.”
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.